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In Brief
The k-opioid receptor (KOR) was used as
a template to generate a novel inhibitory
DREADD (KORD), which is activated by
salvinorin B and insensitive to
endogenous opioid peptides. Sequential
activation of the inhibitory KOR-DREADD
and an excitatory M3-DREADD facilitated
the bidirectional, multiplexed modulation
of behavior.
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DREADDs are chemogenetic tools widely used to
remotely control cellular signaling, neuronal activity,
and behavior. Here we used a structure-based
approach to develop a new Gi-coupled DREADD us-
ing the kappa-opioid receptor as a template (KORD)
that is activated by the pharmacologically inert
ligand salvinorin B (SALB). Activation of virally ex-
pressed KORD in several neuronal contexts robustly
attenuated neuronal activity and modified behaviors.
Additionally, co-expression of the KORD and the
Gq-coupled M3-DREADD within the same neuronal
population facilitated the sequential and bidirec-
tional remote control of behavior. The availability of
DREADDs activated by different ligands provides
enhanced opportunities for investigating diverse
physiological systems using multiplexed chemoge-
netic actuators.
INTRODUCTION
Over the past several years, optogenetic and chemogenetic
(Armbruster et al., 2007; Boyden et al., 2005) approaches have
transformed neuroscience and other disciplines by facilitating
the reversible, cell type-specific control of cellular signaling
and electrical activity. As complementary technologies, opto-
and chemogenetics have demonstrated robust utility for decon-
structing the neuronal codes responsible for both simple and
complex behaviors (Deisseroth, 2011; Sternson and Roth,
2014). The chemogenetic platform known as DREADDs
(designer receptors exclusively activated by designer drugs)
has proven to be extremely useful for interrogating cellular936 Neuron 86, 936–946, May 20, 2015 ª2015 Elsevier Inc.signaling in cell types as diverse as glia (Agulhon et al., 2013),
pancreatic b-cells (Guettier et al., 2009; Jain et al., 2013), hepa-
tocytes (Li et al., 2013), triple-negative breast cancer cells (Yagi
et al., 2011), transformed fibroblasts (Vaque´ et al., 2013), and
induced pluripotent stem (iPS) cells (Dell’Anno et al., 2014).
Current DREADDs, activated by the inert clozapine metabolite
clozapine-N-oxide (CNO), can silence (Armbruster et al., 2007)
or enhance (Alexander et al., 2009) neuronal firing, and can
modulate cellular signaling via Gi, Gq, Gs, or b-arrestin cascades
(Guettier et al., 2009; Nakajima and Wess, 2012). However, the
dependence of DREADD technology on the same inert ligand
CNO limits its effectiveness for bidirectional and multiplexed
chemogenetic control of neuronal and non-neuronal activity.
Thus, the development of a new DREADD that can be activated
by a distinct chemotype would represent a powerful new tool for
neuroscientists and biologists in general.
The first chemogenetic tool based on a G protein-coupled
receptor (GPCR) was developed by Strader and colleagues in
1991 (Strader et al., 1991). Since then, many orthologous recep-
tor-ligand pairs have been developed (e.g., RASSLs, TRECs,
neoceptors, and so on; Conklin et al., 2008), though with occa-
sionally limited utility. Common problems associated with these
first-generation chemogenetic tools included the following:
(1) Many of the synthetic compounds that activate the modi-
fied receptors exhibit appreciable affinities and potencies
for the native receptors. This nonselective activity limits
their efficacy in vivo because of the need to employ
knockout animals in order to avoid activation of endoge-
nous receptors.
(2) In some cases, ligand potency was too low to be useful for
studies in vivo.
(3) The selectivity profile of the ligands was typically unspec-
ified (e.g., they may have activities at other unidentified
cellular targets).
(4) Many of the previously reported modified receptors had
high basal signaling in vivo that obscures ligand-induced
phenotypes (Rogan and Roth, 2011).
The recent development of engineered ligand-gated ion chan-
nels (PSAMs and PSEMs) overcomesmany of these deficiencies
(Magnus et al., 2011), although because PSAMs and PSEMs are
ion channels, they have limited value in non-excitable cells.
Here we reveal the development of a new DREADD using the
k-opioid receptor (KOR) as a template that is activated by salvi-
norin B (SALB). Since SALB is an inactive, drug-likemetabolite of
the KOR-selective agonist salvinorin A (SALA) (Ansonoff et al.,
2006; Roth et al., 2002), and because SALB has excellent CNS
penetrability and pharmacokinetic properties in both rodents
and non-human primates (Hooker et al., 2009), the SALB/
KORD combination will be exceptionally suited for a variety of
contexts. Additionally, the SALB/KORD pairing facilitates the
multiplexed chemogenetic interrogation of GPCR signaling and
behavior.RESULTS
SALB Is Inert In Vivo
Previous preliminary studies showed that SALB is pharmaco-
logically inert in vitro and in vivo (Ansonoff et al., 2006). To verify
and extend these findings, we profiled SALB against a large
number of CNS molecular targets using the resources of the Na-
tional Institute of Mental Health Psychoactive Drug Screening
Program as described in Besnard et al. (2012) and Keiser
et al. (2009). SALB failed to show any activity except the previ-
ously reported low KOR [3H]-diprenorphine radioligand binding
affinity (Ki = 2.95 mM; Figure 1H). Importantly, SALB was also
inactive at muscarinic receptor-based DREADDs (Gq, Gi, and
Gs DREADDs; Figure S1). We found that SALB is a weak KOR
agonist with an EC50 of 248 nM (Figure 1D; Table 1). Importantly,
the potency of SALB is so weak that even after i.c.v. administra-
tion SALB failed to produce KOR-mediated anti-nociception,
while SALA (its active precursor) was potently analgesic (Anson-
off et al., 2006).
Given both the weak potency of SALB at wild-type (WT) KOR
and its inactivity when administered i.c.v., we reasoned that
SALB will be inactive in vivo. To test this hypothesis, we used
several behavioral assays to determine whether SALB can
induce behavioral effects commonly associated with KOR
agonists: analgesia, impairment of motor performance, and the
production of anhedonic-like states. First, we measured the
analgesic and ataxic effects of SALB and compared its activity
with a metabolically stable SALA analog, MOM-ether SALB
(MOM-B), using hot plate and rotarod assays, respectively.
While 2.0 mg/kg MOM-B produced effects in both the hot
plate and rotarod tests, administration of 10.0 mg/kg SALB did
not alter performance relative to controls (Figures 1A and 1B).
Subsequently, we used the curve-shift method of intracranial
self-stimulation (ICSS) to detect reward-devaluing effects of
SALB. While SALA (0.1–1.0 mg/kg) significantly elevated brain
stimulation reward thresholds in C57BL/6J mice at all doses
tested (F3, 18 = 14.5, p < 0.001; Figures 1C and S4), SALB (3.0–
17.0 mg/kg) failed to significantly elevate thresholds up to17.0 mg/kg s.c. Given that SALB is apparently inert in vivo,
and because of its outstanding pharmacokinetic and CNS pene-
trability properties (Hooker et al., 2009), we predicted that SALB
would represent a suitable ligand for a new DREADD.
Structure-Based Design of KORD
In order to develop a new DREADD, we initially hoped to evolve
the human KOR (hKOR) to be responsive to SALB using our
yeast-based directed molecular evolution approach (Armbruster
et al., 2007; Dong et al., 2010). For these studies, hKOR was
cloned into the yeast expression plasmid p416 and functionally
expressed in a genetically modified strain of S. cerevisiae, which
enables ligand-induced activation of heterologously expressed
mammalian Gi-coupled GPCRs to engage the pheromone-sig-
naling pathway, thereby promoting growth on selective media
(Dong et al., 2010; Erlenbach et al., 2001; Noble et al., 2003).
We created a library of mutant hKOR receptors by randommuta-
genesis, and screened them for activation by SALB. We were
able to identify multiple mutants activated by SALB, although
they all displayed high levels of constitutive activity, rendering
them relatively useless for the studies we envisioned.
Therefore, we employed a rational approach to designing the
KOR DREADD based on our recent crystallographic, mutagen-
esis, and molecular modeling studies of hKOR (Vardy et al.,
2013; Wu et al., 2012). These studies showed that an alanine
mutation at E297 at the extracellular end of TM6 (an important
residue in KOR specificity determinant, in the so-called ‘‘address
domain’’; Larson et al., 2000) causes a 10-fold decrease in the
affinity and potency of the endogenous peptide ligand dynorphin
A (DYNA) without altering the affinity or potency of SALA (Vardy
et al., 2013). Another residue, D138 in TM3, which belongs to the
general opioid activation determinant, was also examined. This
residue resides in the ‘‘message domain’’ of KOR (Portoghese,
1989; Vardy et al., 2013), and D138A mutations have been re-
ported to nearly abolish the binding of all known KOR agonists
without affecting the affinity or potency of SALA (Kane et al.,
2006; Vardy et al., 2013). Furthermore, recent high-resolution
crystal structures of related opioid receptors (Fenalti et al.,
2014, 2015) implied that this residue is also essential for the inter-
action of other classes of opioids including opioid peptides and
opioid antagonists. We reasoned, therefore, that changing the
negative charge to a polar residue via a D138N mutation would
further decrease the potency of endogenous peptide ligands
and enhance the potency of SALB and SALA.
Indeed, the D138N mutation apparently abolished DYNA
(1–13) agonist efficacy and potency and diminished peptide
binding affinity while enhancing SALA and SALB affinities and
potencies 10- to 30-fold (see Figures 1D and 1F–1H; Table 1).
As a key requisite of DREADDs is the failure to be activated by
endogenous neurotransmitters, we combined these two KOR
mutants (e.g., D138N/E297A) and evaluated the resulting
construct. Both the double D138N/E297A mutant and the single
D138N mutant responded to SALB and SALA with greatly
enhanced potencies compared to WT, while the E297A mutant
alone had no effect on SALB agonist potency (Figure 1D). Criti-
cally, the single D138N mutant was not activated by any
tested synthetic or endogenous peptide KOR ligands (Figure 1G;
Table 1). Thus, in a screen of 21 endogenous opioids performedNeuron 86, 936–946, May 20, 2015 ª2015 Elsevier Inc. 937
Figure 1. Rational Design and In Vitro Characterization of KORD
(A and B) SALB was initially validated as a DREADD ligand by demonstrating its apparent pharmacologic inertness in vivo using behavioral tests by comparing
with MOM-SALB via (A) hot plate test and (B) impairment of motor performance using the rotarod test. In both tests SALB effects (red) were compared to vehicle
(white) and a stabilized variant of SALA (MOM-SALB, black).
(C) The lack of production of a KOR-like anhedonic state was tested using ICSS and compared to the effects of SALA. Data represent mean ± SEM of indicated
number of separate experiments.
(D) We characterized the KORD comparing the Gi-mediated response of different KOR mutants and demonstrate an increased potency of SALB at D138N-
containing mutants.
(E) The effect of receptor expression levels on SALB potency of WT KOR (gray) and KORD (red). As can be seen, DNA concentration is directly related in bothWT-
KOR and KORD to agonist potency yielding a right shift in potency of 1–2 orders of magnitude.
(F and G) Average Gi response ofWT-KOR (F) and KORD (G) to classic KOR ligands dynorphin A (DYNA, black), SALA (green), and the inert compound SALB (red)
is shown.
(H–J) (H) Competition binding isotherms ofWT and KORD for DYNA (1–13) (pKi values, 8.50 ± 0.12 and 5.79 ± 0.06, respectively) and SALB (pKi values, 5.53 ± 0.08
and 6.98 ± 0.13, respectively). An examination of a model of KORD docked with SALB (I) suggests that the DREADD mutation (D138N) eliminates unfavorable
interactions between D138 and SALB. In WT KOR, D138 is turned away from the ligand-binding site (cyan), while N138 in KORD (white) is interacting directly with
the ligand. E297 in both models assumes the same conformation reflecting the fact that it has no effect on DREADD activity. Deacetylation at position 2 of SALA
results in SALB (J). Asterisk indicates p < 0.05, and all values reported as mean ± S.E.M.at WT and the D138N mutants, no opioid peptide was found to
have detectible agonist activity at the D138N mutant (Table 1;
Figure 1G). As the D138N mutant is potently activated by the
inactive drug SALB and apparently not activated by any tested
endogenous peptide agonist, we chose it as our candidate
DREADD and have dubbed it KORD (k-opioid DREADD).
GPCR overexpression typically results in a large degree of
receptor reserve thereby enhancing agonist potency. Thus,
because a high level of receptor reserve can be easily achieved938 Neuron 86, 936–946, May 20, 2015 ª2015 Elsevier Inc.for DREADDs via virally mediated transduction, receptor reserve
could further enhance the apparent affinity, selectivity, and
potency of SALB for the KORD. To test this notion, we trans-
fected HEK293T cells with increasing concentrations of plas-
mids expressing either WT hKOR or the KORD (D138N hKOR),
which resulted in varying levels of receptor expression. As pre-
dicted, increased receptor expression levels correlated with an
increase in the apparent potency of SALB (Figure 1E). Signifi-
cantly, the potency differences between cells expressing levels
Table 1. KORD Is Insensitive to Endogenous Opioid Peptides and Is Potently Activated by SALB
hKOR KORD
EC50 (nM) pEC50 ± SEM Emax (%) EC50 (nM) pEC50 ± SEM Emax (%)
b-Endorphin (1–27) (b-Endor1–27)
YGGFMTSEKSQTPLVLFKNAIIKNAY
700
6.15 ± 0.22
100 NA NA
b-Endorphin (1–31) (b-Endor1–31)
YGGFMTSEKSQTPLVLFKNAIIKNAYKKGE
706
6.15 ± 0.17
100 NA NA
Leu-enkephalin (Leu-Enk) YGGFL NA NA NA NA
Met-enkephalin (Met-Enk) YGGFM 2,099
5.68 ± 0.12
79 NA NA
Met-enkephalin-Arg-Phe (MERF) YGGFMRF 1,344
5.87 ± 0.14
99 NA NA
Metorphamide YGGFMRRV-NH2 108
6.99 ± 0.07
97 NA NA
BAM 12 YGGFMRRVGRPE 101
6.99 ± 0.07
99 NA NA
BAM 18 YGGFMRRVGRPEWWMDYQ 85
7.07 ± 0.09
97 NA NA
BAM 22 YGGFMRRVGRPEWWMDYQRYG 93
7.03 ± 0.07
95 NA NA
Peptide E YGGFMRRVGRPEWWMDYQRYGGFL 65
7.18 ± 0.07
95 NA NA
Dynorphin A(1–6) (DynA1–6) YGGFLR 227
6.64 ± 0.24
86 NA NA
Dynorphin A(1–7) (DynA1–7) YGGFLRR 107
6.97 ± 0.04
97 NA NA
Dynorphin A(1–8) (DynA1–8) YGGFLRRI 122
6.91 ± 0.06
94 NA NA
Dynorphin A(1–9) (DynA1–9) TGGFLRRIR 127
6.89 ± 0.07
93 NA NA
Dynorphin A(1–13) (DynA1–13) YGGFLRRIRPKLK 19
7.71 ± 0.06
94 NA NA
Dynorphin A(1–17) (DynA1–17) YGGFLRRIRPKLKWDNQ 13
7.87 ± 0.09
100 NA NA
Dynorphin B(1–13) (DynB1–13) YGGFLRRQFKVVT 120
6.91 ± 0.08
100 NA NA
Leumorphin YGGFLRRQFKVVTRSQEDPNAYYEELFDV 21
97.68 ± 0.06
92 NA NA
a-Neoendrophin (a-neo-End) YGGFLRKYPK 64
7.19 ± 0.07
95 NA NA
Endomorphin-1 YPWF NA NA NA NA
Endomorphin-2 YPFF NA NA NA NA
Nociceptin FGGFTGARKSARKLANQ 1,007
5.99 ± 0.07
81 NA NA
U69593 3.16
8.5 ± 0.1
100 > 10,000 NA
Salvinorin B (low expression) 2,045
5.68 ± 0.18
80 160
6.79 ± 0.13
94
Salvinorin B (high expression) 248
6.6 ± 0.1
100 11.8
7.98 ± 0.09
100
Salvinorin A (low expression) 19.8
7.71 ± 0.08
100 0.12
9.91 ± 0.08
100
Salvinorin A (high expression) 1.05
8.96 ± 0.08
100 0.04
10.35 ± 0.08
100
NA, no activation at 10 mM. Data represent mean EC50 andmean pEC50 ± SEM of n = 3 separate 16-point dose-response experiments each performed
in triplicate. hKOR, human k-opioid receptor; KORD, k-opioid receptor DREADD.
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of WT receptor (achieved using 1 mg DNA), which is at a level
similar to endogenous brain expression, versus cells expressing
high levels of the mutant receptor (achieved using 15 mg DNA), is
close to 1,000-fold (Figure 1E). Thus, our rationally designed
KORD greatly enhances hKOR sensitivity to SALB and simulta-
neously abolishes the agonist activity of a variety of endogenous
and exogenous KOR agonists (Figure 1G; Table 1).
As constitutive activity is a potential confounding issue
with respect to overexpressed chemogenetic and optogenetic
tools, we next examined the constitutive activity of KORD
compared to both a WT and a constitutively active KOR mutant
(V108L). We found that the basal activity of KORD (137 ± 3.7 3
105 lumens/min; n = 44; p > 0.05 versus WT) was equivalent to
WT (134 ± 3.2 3 105 lumens/min; n = 48) and less than the
V108L constitutively active mutant (94 ± 3.7 3 105 lumens/min;
n = 50; p < 0.001 versus WT), indicating that the KORD does
not represent an apparently constitutively active mutant.
Although the atomic mechanisms responsible for the increased
affinity and potency for SALB are unknown, our modeling results
suggest that it is likely due to the removal of an unfavorable des-
olvation cost associated with non-basic ligand binding to a
charged aspartate (Asp) (Vardy et al., 2013). Indeed, our docking
studies suggest that changing the Asp at this position to aspar-
agine (Asn) results in an improved conformation for the Asn,
decreases the energetic cost for desolvation, and thus increases
affinity (see Figure 1I).
In Vivo Neuronal Validation of KORD
KORD Activation Induces Neuronal Hyperpolarization
To test the activity of the KORD in vivo, we used a standard Cre-
recombinase-dependent adeno-associated virus (AAV), which
enabled the targeting of KORD to specific neuronal populations
in different Cre-driver mouse lines (Figure 2A). We verified effec-
tive transduction of KORD in a Cre-dependent manner in a vari-
ety of neurons, including the substantia nigra (SN) and the
ventral tegmental area (VTA) of vesicular GABA transporter
(VGAT)-ires-Cre mice (Figures 2B and 2C), the paraventricular
hypothalamus (PVH) of single-minded1 (SIM1)-Cre mice (Balth-
asar et al., 2005), and the arcuate nucleus (ARC) of agouti-
related peptide (AGRP)-ires-Cre mice (Tong et al., 2008) (Figures
3A, 3B, 3E, and 3F).
We next performed whole-cell patch clamp recordings in
acutely prepared slices to test the ability of KORD to generate
a SALB-induced hyperpolarization. Results were calculated
as a shift from baseline resting membrane potential (RMP). In
VTA/SN-VGAT-expressing (VTA/SNVGAT) neurons transduced
with KORD, bath application of SALB led to a robust and signif-
icant membrane potential hyperpolarization, while SALB had
no effect on control (mCherry-transduced) neurons (t9 = 2.97,
p < 0.05; Figure 2D). To determine the generalizability of
KORD-mediated hyperpolarization, we also evaluated SIM1-ex-
pressing neurons in the PVH (PVHSIM1) and AgRP-expressing
neurons in the ARC (ARCAgRP). Upon bath application of
SALB, both PVHSIM1 and ARCAgRP neurons expressing KORD
exhibited robust hyperpolarization, shifting 6.2 ± 2.1 mV and
10.1 ± 1.7 mV, respectively (PVHSIM1, t5 = 2.99, p < 0.05;
ARCAgRP, t4 = 5.94, p < 0.05; Figures 3D and 3H). Next, we
sought to determine if the KORD can act presynaptically to940 Neuron 86, 936–946, May 20, 2015 ª2015 Elsevier Inc.inhibit neurotransmission by recording miniature inhibitory post-
synaptic currents (mIPSCs) in VTA/SN neurons in the presence
of SALB. In VGAT-ires-Cre mice with AAV-hSyn-DIO-KORD
injected into the VTA/SN, SALB significantly reduced mIPSC
frequency (t2 = 24.7, p < 0.001; Figure 2E), but not amplitude
(t2 = 2.45, p > 0.05) compared to baseline, consistent with a
presynaptic effect. SALB had no effect on mIPSCs in naive
mice (frequency, t2 = 0.92, p > 0.05; amplitude, t2 = 4.1, p >
0.05). No differences in baseline mIPSC frequency were
observed between AAV-hSyn-DIO-KORD-injected mice and
naive mice (Figure 2E).
Peripheral SALB Administration Produces Robust
Behavioral Responses
Given that SALB induced KORD-mediated hyperpolarization,
we next tested whether the SALB-induced activation of KORD
had functional consequences on three distinct neuronal
populations: (1) VTA/SNVGAT, (2) hypothalamic PVHSIM1, and (3)
hypothalamic ARCAgRP (using VGAT-ires-Cre, SIM1-Cre, and
AGRP-ires-Cre mice, respectively). Since previous studies
have demonstrated that optogenetic modulation of VTA/SNVGAT
neurons can modify locomotion (van Zessen et al., 2012), we
predicted that chemogenetic silencing via KORD of VTA/SNVGAT
neurons (Figures 2B and 2C) would increase locomotion. As ex-
pected, SALB produced a dose-dependent increase in locomo-
tor activity (F3, 21 = 19.1, p < 0.001) (Figure 2F), while vehicle was
without effect; post hoc testing revealed that the 1.0-, 3.0-, and
10.0-mg/kg SALB doses significantly enhanced locomotion.
Importantly, mice expressing mCherry in the same neuronal
population were unresponsive to SALB (Figure 4B).
Next, we evaluated KORD activity in a neural circuit known to
be involved in feeding behavior. PVHSIM1 neurons (Figures 3A
and 3B), which make up the vast majority of PVH cells, have
been previously demonstrated to increase food intake when
chemogenetically inhibited (Atasoy et al., 2012; Stachniak et al.,
2014). Consistent with prior results obtained using hM4Di,
SALB activation of KORD in PVHSIM1 neurons significantly
increased feeding behavior compared to baseline (0.61 ±
0.04 g versus 0.06 ± 0.01 g; t6 = 11.8, p < 0.05; Figure 3C),
whereas WT control mice (t5 = 0.30, p < 0.05) injected with the
Cre-dependent KORD virus had no feeding effects in response
to the administration of SALB.
As a final test, we evaluated the orexigenic ARCAgRP neurons
(Figures 3E and 3F), which have been shown to send inhibitory
projections to the PVH and synapse onto a subpopulation
of PVHSIM1 neurons (Krashes et al., 2014; Atasoy et al., 2012).
Having established that activation of KORD hyperpolarizes
PVHSIM1 neurons in vitro and increases food intake in vivo, we
next tested KORD activation with SALB on the upstream inhibi-
tory ARCAgRP neurons (Figures 3G and S2). Following light cycle
food restriction, food consumption was monitored during the
first 60 min of the dark cycle, when mice normally eat
and ARCAgRP neural activity is high (Krashes et al., 2011).
Compared to vehicle (0.59 ± 0.07 g), KORD inhibition of the hun-
ger-promoting ARCAgRP neurons resulted in significantly dimin-
ished levels of food intake (0.11 ± 0.03 g; t5 = 11.29, p < 0.05).
Importantly, SALB administration did not impact feeding re-
sponses in WT animals (vehicle, 0.52 ± 0.05 g; SALB, 0.55 ±
0.07 g).
Figure 2. Validation of KORD In Vivo in VTA/SNVGAT Neurons
(A) Schematic showing the AAV8 (hSyn-DIO-hKORD-IRES-mCit-WPRE-PolyA-R-ITR) construct used and its recombination under the control of Cre-
recombinase.
(B) Location for viral infusion of Cre-expressing VTA/SNVGAT neurons.
(C) Representative low-power field of VTA/SNVGAT neurons.
(D) Shift from baseline resting membrane potential (RMP) in VTA/SNVGAT neurons transduced with KORD or mCherry (control) constructs.
(E) Baseline mIPSC frequency in non-KORD-expressing neurons in KORD-infectedmice and control neurons from naivemice controls and the effects of SALB on
miniature IPSC frequency and amplitude in uninfected VTA/SNVGAT and naive control VTA/SN neurons.
(F) Locomotor responses for graded doses of SALB. Asterisk indicates p < 0.05, and all values reported as mean ± S.E.M.
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Figure 3. Validation of KORD In Vivo in
PVHSIM1- and ARCAgRP-Expressing Neurons
(A) Location for viral infusion of PVHSIM1 Cre-
expressing neurons.
(B) Representative immunofluorescent photomi-
crographs demonstrating expression of mCitrine
in virally transduced neurons.
(C) Effects of SALB on food intake in AAV-hSyn-
DIO-KORD-injected SIM1-Cre and WT mice.
(D) Shift from baseline resting membrane potential
(RMP) in KORD-transduced neurons in the
PVHSIM1.
(E and F) Location of viral infusion and expression
of mCitrine (green) and HA-hKORD (red) in
ARCAgRP neurons.
(G) Suppression of food intake by SALB.
(H) Shift from baseline RMP in KORD-transduced
neurons in the ARCAgRP. Asterisk indicates p <
0.05, and all values represent mean ± S.E.M.KORD Facilitates Chemogenetic Multiplexed Control of
Behavior
One of our main goals for developing the KORD was to enable
multiplexingexperiments for either thesimultaneousor sequential
manipulation of neuronal pathways using a variety of chemo- and
optogenetic platforms. To test whether two distinct DREADDs
can reciprocally modulate neuronal activity and behavior
in vivo, we transduced VTA/SNVGAT neurons or hypothalamic
ARCAgRPneuronswithboth the inhibitory,Gi-coupled,SALB-acti-
vated KORD and the stimulatory, Gq-coupled, CNO-activated
hM3Dq. We then tested for receptor expression and behavioral
effects.
We found that locomotor activity could be bidirectionally
modulated by KORD and hM3Dq in the same mouse. During
different testing sessions, SALB (10.0 mg/kg) enhanced locomo-
tor activity inmice that expressedbothKORDandhM3Dq inVTA/
SNVGAT neurons compared to vehicle (t4 = 2.89, p = 0.04; Fig-
ure 4B), and CNO (3.0 mg/kg) decreased locomotor activity
(t4 = 5.44, p = 0.006). When tested during the same session,
CNO (3.0 mg/kg) produced significant locomotor depression
(t4 = 3.28, p = 0.03), while SALB (17.0 mg/kg) rescued the effects
of CNO and significantly elevated locomotor activity when
compared to vehicle (t4 = 3.44, p = 0.03; Figures 4C and 4D). In
these sessions, the onset of action of both CNOand SALBbegan
influencing locomotor behavior within 10–20 min post-injection.
Importantly, neither SALB (10.0 mg/kg; t5 = 1.93, p > 0.05) nor
CNO (3.0 mg/kg; t5 = 0.95, p > 0.05) had any effect on locomotor
activity in control mice expressing mCherry in VTA/SNVGAT neu-
rons (Figure 4B). Histologic analysis of VTA/SNVGAT neurons
showed that 87.7%±1.7%of transduced neurons co-expressed
both receptors with no significant difference in the transduction
efficiency of either DREADD (t2 = 0.82, p > 0.05; Figure S3). These
results demonstrate for the first time that twodifferent biologically
inert designer ligands can produce robust behavioral changes in
the same mouse, providing the first proof of concept for multi-
plexed chemogenetic control of behavior.
We next investigated the effectiveness of multiplex manipula-
tion of behavior while transducing ARCAgRP neurons with both
the hM3Dq and KORD. As acute opto- and chemogenetic acti-
vation of ARCAgRP neurons drives feeding behavior (Aponte942 Neuron 86, 936–946, May 20, 2015 ª2015 Elsevier Inc.et al., 2011; Betley et al., 2013; Krashes et al., 2011), we attemp-
ted to reverse ARCAgRP hM3Dq activation-induced feeding
with simultaneous KORD inhibition. Importantly, for this experi-
ment to work, extensive restraint of ARCAgRP neuron activity is
necessary to overcome the chemogenetically induced feeding
response, given that only 10% of ARCAgRP neurons are
required to drive the full magnitude of food intake (Aponte
et al., 2011; Betley et al., 2013). Consistent with previous studies,
CNO/hM3Dq-induced activation of ARCAgRP neurons increased
light cycle food intake (0.75 ± 0.03 g) significantly compared to
saline baseline (0.04 ± 0.02 g; Time, F6, 108 = 108.4; Treatment,
F1, 18 = 10.6; and Time 3 Treatment, F6, 108 = 4.5; F6, 108 =
62.1, p < 0.001 for all; Figure 4E). However, co-administration
of CNO and SALB significantly blunted feeding behavior (CNO
versus CNO + SalB; Time, F6, 108 = 80.9; Treatment, F1, 18 =
204.3; and Time 3 Treatment, F6, 108 = 62.1; p < 0.001 for all).
Post hoc testing revealed a significant reduction of food intake
similar to that observed during simultaneous optogenetic activa-
tion and hM4Di-mediated inhibition of ARCAgRP neurons (Stach-
niak et al., 2014). Interestingly, these animals elevate their
feeding rate in the next 2 hr (1–3 hr after ligand injection), reflect-
ing both the transient action of SALB/KORD and persistent
action of CNO/hM3Dq (Figure 4E).
DISCUSSION
Here we report the development of a new chemogenetic tool
based on the KOR we have dubbed KORD (k-opioid DREADD).
We demonstrate that KORD can be used alone or in conjunc-
tion with other chemogenetic tools, thereby facilitating the
multiplexed dissection of neural circuitry and behavior. As
KORD is activated by SALB, it can be used in mice also express-
ing CNO-responsive DREADDs, allowing for the first time
bidirectional chemogenetic manipulation of neural circuits.
Although bidirectional control has only been demonstrated in
the hypothalamus and VTA/SN, it is likely that this approach
will work in other brain regions. The KORD could also be used
together with other chemogenetic and optogenetic tools in
order to provide higher-order multiplexed modulation of GPCR
signaling in non-neuronal cells.
Figure 4. Multiplexed Bidirectional Chemo-
genetic Control of Behavior
(A) Representative immunofluorescent confocal
micrographs wherein hM3Dq and KORD were
co-expressed in VTA/SNVGAT neurons with co-
localization data summarized in Figure S3.
(B) Comparison of the effects of CNO and SALB on
spontaneous locomotor activity of dual DREADD-
expressing mice (right panel; mice expressing
both hM3Dq andKORD in VTA/SNVGAT neurons) or
control mice (mCherry; left panel). CNO inhibits
spontaneous locomotor behavior, and SALB
augments locomotor behavior on different testing
days (right panel). CNO and SALB did not affect
behavior in mice that expressed mCherry in the
same brain region.
(C) Bidirectional manipulation of locomotor
behavior: the locomotor activity of dual DREADD-
expressing mice was inhibited by CNO (CNO in-
jection at 60 min). The locomotor depression was
reversed by SALB injection (SALB injection 30 min
after CNO injection).
(D) Summary data of locomotor activity experi-
ments using multiplexed DREADDs.
(E) Demonstration that SALB inhibits food intake induced by CNO-mediated activation of hM3Dq when both are expressed in ARCAgRP neurons; these
effects show transient effects of SALB versus the persistent effects of CNO. Asterisk indicates p < 0.05, and all values represent mean ± S.E.M.The kinetics of CNO on neuronal activation via hM3Dq have
been demonstrated thoroughly by a large number of indepen-
dent studies, with in vivo DREADD-mediated responses begin-
ning 5–10 min after IP injection, and peak electrophysiological
response occurring 45–50 min after injection (Alexander et al.,
2009; Urban and Roth, 2015). It has also been reported by
many labs that both the behavioral and electrophysiological
effects of CNO-mediated DREADD activation can persist for
several hours following a single injection in a manner predicted
by its pharmacokinetic properties (Urban and Roth, 2015). By
contrast, SALA and SALB concentrations in the rodent and pri-
mate brain increase within a few seconds following parenteral
administration and then rapidly decline (t1/2 = 10–15 min; Hooker
et al., 2009). Likewise, the behavioral effects of SALB in KORD-
expressing mice begin and peak shortly after injection, yielding a
behavioral effect that lasts for approximately 1 hr with the doses
administered here. As a prolonged activation of DREADDs by
CNO may be a problem when studying rapidly modulated,
short-term behaviors, the apparently brisk onset of the effects
of SALB in KORD-expressing mice may prove valuable for
such studies. Indeed, prior studies have demonstrated that
SALB is cleared quickly from the brain, but has a slightly more
prolonged plasma half-life (Hooker et al., 2009), and thus its
pharmacokinetic properties may be better suited for studies in
which relatively acute neuronal silencing is required, while
CNO-based DREADDs (e.g., hM4Di) are useful where prolonged
silencing is desired.
Given that SALB has some modest activity at KOR, it is
possible that neurons with a high degree of receptor reserve
could show responses to high systemically administered doses
of SALB. Even though we have been unable to detect any phar-
macological effect of SALB administration, it will be important to
avoid using excessively high doses (e.g., > 10 mg/kg) and to test
SALB in animals in which KORD has not been expressed. Addi-tionally, because of the limited solubility of SALB, it will be impor-
tant going forward to develop analogs of SALB which show
improved water solubility.
Optogenetic and chemogenetic tools have revolutionized
neuroscience research by facilitating the region- and cell type-
specific manipulation of neuronal activity. Optogenetics pro-
vides inherent advantages with millisecond temporal resolution,
although the hardware required for precise intracranial light de-
livery is not only invasive, but also cumbersome in comparison
to the minimal requirements for chemogenetic manipulation.
Chemogenetic control via DREADDs provides slower kinetics
due to the systemic administration of CNO or SALB, but has
demonstrated its ability to achieve the same functional mapping
results with less invasive intervention (reviewed by Mahler et al.,
2014; Stachniak et al., 2014; Urban and Roth, 2015). It is also
possible to directly infuse CNO into specific brain structures to
obtain a transient and focal DREADD activation. The newly
developed KORD described here provides potentially greater
temporal resolution compared to existing DREADDs, as SALB
pharmacokinetics are relatively rapid; additionally, the KORD’s
effects are apparently robust. Finally, given the relative simplicity
of multiplexing with bimodal control now easily achievable, the
KORD will prove broadly useful for neuroscientists and other
biologists.EXPERIMENTAL PROCEDURES
Molecular Methods
Molecular Biology
Mutagenesis, radioligand binding, and functional assays were done exactly as
described in Vardy et al. (2013).
Molecular Modeling
Molecular modeling of SALA and SALB in complex with the WT KOR was per-
formed as previously described (Vardy et al., 2013). Modeling of SALA and
SALB in complex with the KORD was achieved by in silico mutation of D138Neuron 86, 936–946, May 20, 2015 ª2015 Elsevier Inc. 943
to N in the respective WT KOR-ligand complexes, with subsequent energy
minimization in SYBYL-X 2.1 (Tripos Force Field, Gasteiger-Hu¨ckel charges,
distance-dependent dielectric constant = 4.0; non-bonded interaction cutoff =
8 A˚; termination criterion = energy gradient < 0.05 kcal/(mol 3 A˚) or 100,000
iterations).
Viral Production Methods
Virus Production
KORD (Table S2) in pcDNA 3.0 was cloned into a human synapsin (hSyn)-
driven double-floxed pAAV vector derived from pAAV-HA-M4D-IRES-mCi-
trine. The pAAV-HA-KORD-IRES-mCitrine was then used for AAV9 production
at the UNC Vector Core as described (Zhu et al., 2014).
Viral Infusion In Vivo
Mice were anesthetized with ketamine (120 mg/kg) and xylazine (18 mg/kg)
(Sigma), and viral constructs (AAV-hSyn-DIO-HA-KOR DREADD, AAV-
hSyn-mCherry, or AAV-hSyn-KOR DREADD + AAV-hSyn-hM3D) were
stereotaxically injected bilaterally into the VTA/SN, or hypothalamic PVH or
ARC (coordinates for VTA/SN: AP 3.1, ML ± 0.4, DV 5.0; coordinates for
PVH: AP 0.65, ML ± 0.2, DV 4.7; coordinates for ARC: AP 1.5, ML ±
0.3, DV 5.7) using a 1.0-ml Hamilton Neuros 7001 KH syringe at a volume
of 300 nL/side, at a rate of 100 nL/min for the VTA/SN; 25 nL/side, at a rate
of 50 nL/min for the PVH; and 200 nL/side, at a rate of 50 nL/min for the
ARC. After surgery, mice were returned to their cages for 2–3 weeks of recov-
ery before behavioral or electrophysiological testing.
Slide Preparation and Immunohistochemistry
Animals were deeply anesthetized with an overdose of ketamine (400 mg/kg)
and xylazine (40 mg/kg) and transcardially perfused with PBS (4C, pH 7.4) fol-
lowed by 4% PFA in 0.1 M phosphate buffer (4C, pH 7.4). Brains were post-
fixed overnight in 4%PFA, and subsequently cryopreserved in 30% sucrose in
0.1 M phosphate buffer. For confocal image collection, tissue sections con-
taining the VTA/SN were cut into 40-mm sections using a sliding microtome
(Leica SM2010 R) and stored in an ethylene glycol/sucrose-based cryoprotec-
tant. For immunohistochemistry, tissue sections were washed in PBS (pH 7.4)
three times, followed by 30 min of permeabilization in PBS with 0.3% Triton-X.
Tissue sections were blocked in 5% normal donkey serum and PBSwith 0.3%
Triton-X for 1 hr, and incubated with 1:500 rabbit anti-HA (Cell Signaling, cat#
3724S, RRID: AB_1549585) and 1:500 mouse anti-mCherry (Abcam, cat#
ab125096, RRID: AB_11133266) for 48 hr at 4C. Subsequently, tissues
were washed three times for 5 min in PBS with 0.3% Triton-X, and then incu-
bated with Alexa 568 donkey anti-mouse and Alexa 647 donkey anti-rabbit
secondary antibodies (1:250) for 24 hr at 4C. Tissue sections were washed
three times for 5 min in PBS with 0.3% Triton-X, followed by two 5-min washes
with PBS (pH 7.4). A DAPI counterstain (300 nM) was applied in the first PBS
wash step. Whole-tissue sections were imaged with an epifluorescent slide
scanner at the UNC translational pathology lab. Confocal images of infected
midbrain GABAergic neurons were taken using a Fluoview FV1000 with a
403 (NA 1.3) oil objective. To show co-expression of mCitrine and the HA-
tagged KORD, the same staining protocol was observed, substituting an
anti-GFP antibody recognizing mCitrine.
Quantification of Co-expression of M3-DREADD and KORDs
A total of three 40-mm sections containing the VTA/SN were taken from brains
of three mice who had received multiplexed DREADD injections. In each sec-
tion, a z stack was collected in the VTA using a 403 oil objective (3003 300 mm
field of view). Co-expression of DREADDs was calculated by counting total
transduced cells (either KOR or M3 positive) and calculating the relative
percentages expressing KOR alone, M3 alone, or KOR/M3. Cell counts were
averaged within each animal, and data were analyzed using a Student’s paired
t test.
Behavioral Studies
SALB Evaluation in Control Mice
The analgesic-like effect of KOR-specific drugs was determined measuring
the heat sensitivity of mice in a hot plate assay as previously described (White
et al., 2015). The effect of such drugs on balance and motor coordination was
assessed by the rotarod test (White et al., 2015). KOR activation has been
strongly related to anhedonia (Todtenkopf et al., 2004); the anhedonic effects944 Neuron 86, 936–946, May 20, 2015 ª2015 Elsevier Inc.of KOR agonists were measured by ICSS in mice as previously described
(Robinson et al., 2012). This operant behavioral method measures the value
of electrical stimulation (brain stimulation reward or BSR) applied to the fibers
of the medial forebrain bundle (MFB) at the level of the lateral hypothalamus
and can be used to assess the reward-potentiating or reward-devaluing ef-
fects of drugs.
Animals
Adult (at least post-natal day 50) male and female Slc32a1tm2(cre)Lowl/J (VGAT-
ires-Cre; provided by Dr. Bradford Lowell, Harvard University) littermates were
housed in a temperature- and humidity-controlled environment under a 12-hr
light/dark cycle and had free access to food and water. All procedures were
approved by the Institutional Animal Care and Use Committee (IACUC) of
the University of North Carolina at Chapel Hill, the National Institute of Diabetes
and Digestive and Kidney Diseases, or the National Institute on Drug Abuse,
and were conducted according to the Guide for the Care and Use of Labora-
tory Animals (NIH publication no. 85-23, revised 2011).
Locomotor Studies
Locomotor activity was measured before and after treatment with vehicle (s.c.
or i.p.), SALB (1.0–17.0 mg/kg s.c.), or CNO (i.p.) in 28 3 28 cm plexiglass
chambers containing two sets of 16 infrared photobeams (MedAssociates).
Data were collected with software (MED-PC v4.1; MedAssociates) that calcu-
lated the total distance traveled (cm) by measuring the position of the mouse
every 60 ms. During test sessions mice were placed into the center of the
chamber, and locomotion was measured for 60 min. During single-drug expo-
sure sessions, mice were removed from the chambers, injected with drug
(SALB, 1–10.0 mg/kg; CNO, 3.0 mg/kg; or vehicle), and returned to the cham-
ber for 60 min of testing. During two-drug exposure sessions, mice were
removed from the chambers after a 60-min baseline, injected with vehicle or
3.0 mg/kg CNO, returned to apparatus for 30 min, removed, injected with
17.0 mg/kg SALB or vehicle, and returned to the chambers for an additional
30 min of testing. Mice were habituated to vehicle injections for 2 days before
testing. SALB was dissolved in DMSO and injected subcutaneously (s.c.)
through a 27-gauge needle at a volume of 1 mL/g body weight using a Hamilton
GASTIGHT 250-mL syringe. CNO was dissolved in 10% DMSO in saline and
injected i.p. through a 27-gauge needle at a volume of 10 mL/g body weight.
Drugs were administered in counterbalanced order using a within-subjects
design. Drug effects were determined by the total distance traveled during
the 60-min post-injection period or during each 30-min post-injection period.
Dose effects were analyzed with repeated-measures ANOVA with post hoc
Bonferroni t tests when p < 0.05. Individual drug determinations were
compared to vehicle using paired t tests.
Mouse Handling for Feeding Studies
Mice (10- to 12-week-old males) were singly housed for at least 2.5 weeks
following surgery and handled for 10 consecutive days before the assay to
reduce stress response. Feeding studies were performed in home cages
with ad libitum food access. Home cages were changed every day during
food intake measurements to eliminate residual food crumbs in the bedding.
CNO was administered at 1 mg per kg of body weight. Saline was delivered
at the same volume as CNO to maintain consistency in the studies. SALB
was administered at 10 mg/kg, dissolved in DMSO. DMSO was delivered at
the same volume as SALB to maintain consistency. Mice with ‘‘missed’’ viral
injections, incomplete ‘‘hits,’’ or expression outside the area of interest were
excluded from analysis after post hoc examination of mCherry and mCitrine
expression.
Feeding Studies in SIM1-Cre Mice
During the light cycle, animals (SIM1-cre, n = 7; WT, n = 6) were injected with
either DMSO (s.c.) or SALB (10 mg/kg; s.c.), and food intake was measured
1 hr after injection. A full trial consisted of assessing food intake from the study
subjects after they received injections of DMSO on day 1 and SALB on day 2.
Animals received a day ‘‘off’’ between trials before another trial was initiated.
The food intake data from all days following DMSO/SALB injections were
then averaged across four trials and combined for analysis.
Feeding Studies in AGRP-Ires-Cre Mice
Just before the onset of the dark cycle, animals (AGRP-ires-cre, n = 6; WT, n =
6) were injected with either DMSO (s.c.) or SalB (10 mg/kg; s.c.), and food
intake was measured 1 hr after injection. A full trial consisted of assessing
food intake from the study subjects after they received injections of DMSO
on day 1 and SalB on day 2. Animals received a day ‘‘off’’ between trials before
another trial was initiated. The food intake data from all days following DMSO/
SalB injections were then averaged across three trials and combined for
analysis.
Feeding Studies with Multiplexed KOR and hM3Dq DREADD
During the light cycle, animals (AGRP-ires-cre, n = 10) were injected with saline
(i.p.), CNO (1 mg/kg; i.p.), DMSO (s.c.), or CNO + SalB (10 mg/kg; s.c.), and
food intake was monitored every 30 min for 3 hr after s.c. injection. A full trial
consisted of assessing food intake from the study subjects after they received
injections of saline on day 1, CNO on day 2, DMSO on day 3, and CNO + SalB
on day 4. Animals received 3 days ‘‘off’’ between trials before another trial was
initiated. The food intake data from all days were then averaged by condition
across three trials and combined for analysis.
Whole-Cell Electrophysiology Experiments
The ability of KORD to generate a SALB-induced hyperpolarization was tested
using whole-cell electrophysiology. Slices were checked for adequate expres-
sion of the target constructs via the mCitrine fluorescence, and those mice in
which expression of constructs could not be identifiedwere discarded. Using a
potassium gluconate-based internal recording solution, whole-cell electro-
physiological experiments were conducted in current-clamp at the RMP for
each neuron. Following a 5-min stable baseline, 100 nM SALB was bath-
applied for 10 min (VTA/SNVGAT), 6 min (PVHSIM1), or 7 min (ARCAgRP) at a
flow rate of 2 mL per minute. Average RMPs before and after the application
of SALB were calculated, and results were presented as a shift from baseline
RMP. Miniature IPSCs were recorded in the presence of tetrodotoxin (500 nM)
and kynurenic acid (3 mM) to block AMPA and NMDA receptor-dependent
postsynaptic currents. Neurons were held at70 mV across all voltage-clamp
recordings, and recording electrodes were filled with (in mM) 70 KCl, 65 potas-
sium gluconate, 5 NaCl, 10 HEPES, 2 QX-314, 0.6 EGTA, 4 Na-ATP, 0.4 Na-
GTP (pH 7.25), and 290–295 mOsm. After a 6-min stable baseline, SALB
(100 nM) was bath-applied for 15 min, and recordings were continued during
a 20-min washout period. mIPSCs were detected using ClampFit, and the fre-
quency and amplitude of events were normalized to baseline.
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